PRE-CLINICAL IN-VIVO ACUTE TOXICITY AND ANTI-INFLAMMATORY EVALUATION OF AURONE DERIVATIVES

Abstract

This study investigates the acute toxicity and anti-inflammatory potential of aurone derivatives (C-A, M-A and DM-A) using in vivo models. Male Swiss albino BALB/c mice were employed, and ethical clearance was obtained from Abdul Wali Khan University, Mardan. Acute toxicity test was conducted in two Phases. Phase-l for lower dose and Phase-ll for higher doses. For the anti-inflammatory assessment, a carrageenan-induced paw edema and xylene-induced ear edema were performed.

Acute toxicity assay of stated aurones on mice models revealed that these compounds were well-tolerated up to 500 mg/kg, with no observable symptoms of toxicity in terms of mortality and morbidity, thus confirming their safety profile. The aurone derivatives, showed dose dependent potential, particularly DM-A, demonstrated significant anti-inflammatory activity at a dose of 20 mg/kg showing the highest inhibition of paw edema (60.89%)  after 3 hours post-administration as compared to control (3.81±0.07) and standard 1.6±0.15 (58%) in carrageenan assay and reduced significantly (p=0.05) the mice ear edema from 0.301±0.008 to 0.24±0.004 after 40 min of the treatment via xylene induced ear edema assay. This suggests that aurone derivatives may effectively modulate the inflammatory response, likely through the inhibition of pro-inflammatory cytokines or stabilization of cell membranes.

The findings suggest that aurone derivatives possess significant therapeutic potential as anti-inflammatory agents, with a favorable safety profile. These results warrant further investigation into their development as safer alternatives to conventional therapies.